Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Type 3 inflammation–specific keratinocyte glutaminolysis promotes skin inflammation
Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia
Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia
View: Text | PDF
Research Article Dermatology Metabolism

Type 3 inflammation–specific keratinocyte glutaminolysis promotes skin inflammation

  • Text
  • PDF
Abstract

Inflammatory cytokines reprogram keratinocyte metabolism, but the metabolic pathways that couple immune signals to pathological epidermal growth remain incompletely defined. Here, we identify glutaminase 1–mediated (GLS1-mediated) glutaminolysis as a metabolic program preferentially induced in keratinocytes under type 3 inflammatory conditions. Integrated transcriptomic, metabolomic, genetic, and functional analyses showed that IL-17A induced GLS1 expression and glutaminolysis in keratinocytes. Keratinocyte-specific Gls1 deletion reduced the intracellular availability of arginine, proline, and methionine, impaired amino acid–dependent mTORC1 activation, disrupted redox homeostasis, and limited keratinocyte proliferation. Amino acid or antioxidant supplementation partially rescued these defects, whereas rapamycin blocked the amino acid–mediated proliferative rescue. Gls1 deletion did not impair steady-state skin development or homeostasis and did not alter MC903-induced type 2 dermatitis, but it delayed wound re-epithelialization and attenuated imiquimod-induced psoriasiform inflammation. Loss of keratinocyte GLS1 also reduced epidermal chemokine expression and the accumulation of neutrophils and IL-17A–producing γδ T cells, revealing a role for glutaminolysis in amplifying epithelial-immune crosstalk. These findings define GLS1-mediated glutaminolysis as a context-specific metabolic checkpoint linking type 3 inflammation to keratinocyte proliferation and cutaneous immune amplification, and support locally or temporally controlled GLS1 inhibition as a potential therapeutic strategy for psoriasis.

Authors

Yongfei Hu, Hai Yu, Kaiyu Liang, Liyan Yuan, Wenjun Zhang, Zhe Zhuang, Suyun Ji, Xichun Xia

×

Figure 6

Keratinocyte-specific Gls1 deletion attenuates psoriasiform skin inflammation.

Options: View larger image (or click on image) Download as PowerPoint
Keratinocyte-specific Gls1 deletion attenuates psoriasiform skin inflamm...
(A–C) WT and cKO mice were painted on their shaved back skin with IMQ-containing cream for 5 consecutive days (n = 6). Clinical manifestations and histologic sections (H&E staining) of skin lesions (A) (scale bars: 100 mm), PASI scores (B), and acanthosis (C) were recorded. (D) The ears of WT and KO mice were injected intradermally with PBS or IL-23 every other day 5 times (n = 6). Representative photographs of histologic sections (H&E staining) of the ears and acanthosis were measured. (E) Immunohistochemical analysis of Ki-67 expression in epidermis from WT and cKO mice in A (n = 6). (F) Western blot analysis of mTORC1 activation in basal keratinocytes from WT and cKO mice in A (n = 3). (G) LC-MS/MS analysis of amino acids in basal keratinocytes from WT and cKO mice in A (n = 6). (H) Flow cytometry and statistical analysis of the percentage and number of dermal neutrophils (gated on CD45+CD90.2– lymphocytes), IL-17A+ γδ T cells (gated on CD3+TCRγδ+ cells), and IL-17A+CD4+ T cells (gated on CD3+CD4+ cells). (I and J) RT-PCR measurement of chemokine and cytokine expression in basal keratinocytes from WT and cKO mice in A (n = 6). Scale bars: 100 μm (A, D, and E) Data are presented as mean ± SD and representative of 2 independent experiments with consistent results. Statistical significance was determined by 2-way repeated-measures ANOVA followed by Šídák’s multiple-comparison test (B) or 2-tailed Student’s t test (C–E and G–J). *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts